Search

Displaying results 8721 - 8730 of 10000 in total
  1. Drug

    TB-402

    go.drugbank.com/drugs/DB06050
    Investigational

    TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. … It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.

  2. Drug

    DTS-201

    go.drugbank.com/drugs/DB06071
    Experimental

    DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment.

  3. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. … CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far.

  4. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. … PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.

  5. Drug

    Affitope AD01

    go.drugbank.com/drugs/DB06086
    Investigational

    AD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates.

  6. Drug

    Apatorsen

    go.drugbank.com/drugs/DB06094
    Investigational

    Apatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers

  7. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation.

  8. Drug

    YKP-1358

    go.drugbank.com/drugs/DB06109
    Experimental

    YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. … In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.

    Categories: Serotonin 5-HT2 Receptor Antagonists
  9. Drug

    AB192

    go.drugbank.com/drugs/DB06111
    Experimental

    AB192 is a DPP IV enzymatic activity inhibitor.

  10. Drug

    DPI-221

    go.drugbank.com/drugs/DB06121
    Experimental

    DPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 4-((.ALPHA.S)-.ALPHA.-((2S,5R)-2,5-DIMETHYL-4-(3-FLUOROBENZYL)-1-PIPERAZINYL)BENZYL)-N,N-DIETHYLBENZAMIDE, BENZAMIDE, N,N-DIETHYL-4-((S)-((2S,5R)-4-((3-FLUOROPHENYL)METHYL)-2,5-DIMETHYL-1-PIPERAZINYL)PHENYLMETHYL)-